The abstract is read at the publisher; the summary is JClub's.
Lorlatinib first-line therapy in advanced ALK-positive non-small-cell lung cancer shows 7-year PFS of 55% versus 3% with crizotinib, with median PFS not reached.
- Why it matters: Long-term durability beyond 5 years was unclear for first-line ALK inhibitors, especially regarding sustained progression control and intracranial activity.
- What they did: In the phase III CROWN study, 296 treatment-naive patients were randomized 1:1 to lorlatinib 100 mg once daily (n=149) or crizotinib 250 mg twice daily (n=147), with investigator-assessed efficacy, safety, and biomarker analyses at 7 years.
- The result: Median follow-up was 83.0 and 77.2 months, with median PFS NR (95% CI 68.5-NR) on lorlatinib and 9.1 months (95% CI 7.4-10.9) on crizotinib (HR 0.19, 95% CI 0.13-0.26); no new intracranial progression events occurred after 30 months on lorlatinib.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.